Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Time in Range, CGM Metrics for Predicting Outcomes in Diabetes

Time in Range, CGM Metrics for Predicting Outcomes in Diabetes

FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives


Time in Range, CGM Metrics for Predicting Outcomes in Diabetes

FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

ratings:
Length:
15 minutes
Released:
Feb 20, 2024
Format:
Podcast episode

Description

The introduction of CGM in 1999 completely shifted the trajectory of care for people with diabetes. Now, new data suggest advanced CGM metrics, such as time in range, are proving comparable to HbA1c for predicting diabetic retinopathy and other microvascular outcomes.

In this episode, Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range and other advanced CGM metrics with diabetic retinopathy and the implications for use in predicting other microvascular outcomes.

Episode Highlights

00:05 - Intro

02:04 - CGM Data to Predict Diabetes Complications

05:15 - Time in Range and Microvascular Complications

09:36 - Glycemic Variability and Incident Diabetic Retinopathy

12:17 - Time in Range, CGM Data for Predicting CV Outcomes
Released:
Feb 20, 2024
Format:
Podcast episode

Titles in the series (94)

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.